Dishman Carbogen Amcis Q4 FY26 Results and Strategic Financial Restructuring

Dishman Carbogen Amcis has announced its financial results for the quarter and year ended March 31, 2026, alongside strategic updates. The company reported a consolidated annual income of ₹2,987.84 crore for FY26. Key board approvals include a revised CHF 200 million External Commercial Borrowing facility to refinance existing debt and a significant increase in borrowing limits to ₹4,000 crore to support capital requirements.

Financial Performance Overview

For the fiscal year ending March 31, 2026, the company achieved a total consolidated income of ₹2,987.84 crore. The net profit for the year stood at ₹97.45 crore, with a consolidated net profit of ₹21.74 crore reported for the final quarter (Q4). The performance reflects sustained operations across the company’s global CDMO business segments.

Strategic Debt Refinancing

The Board of Directors has approved a major financial initiative to avail an External Commercial Borrowing (ECB) facility of up to CHF 200 million (approximately ₹2,452 crore). This facility, to be provided by the promoter group company Aamanya AG, is specifically designed to refinance existing higher-cost rupee debt, optimize interest expenses, and fund working capital and capital expenditure needs. The loan will be unsecured, carrying an interest rate of SARON + 400 bps with a 10-year maturity.

Enhanced Borrowing Capacity

To provide greater financial flexibility for future growth, the board has passed a resolution to increase the company’s borrowing limits under the Companies Act from the current ₹1,700 crore to ₹4,000 crore. This proposal is subject to approval by the company’s shareholders at an upcoming Extra-Ordinary General Meeting (EGM).

Statutory Auditor Appointment

As part of its governance roadmap, the company has recommended the re-appointment of M/s. T R Chadha & Co. LLP, Chartered Accountants, as the Statutory Auditors for a second term of five consecutive years. This appointment will span from the conclusion of the upcoming 19th Annual General Meeting through to the conclusion of the 24th Annual General Meeting, pending shareholder approval.

Source: BSE

Previous Article

HealthCare Global Enterprises Divestment of BACC Health Care Business

Next Article

Welspun Living Update on Stakeholders Relationship Committee Compliance